Jincheng Pharm(SZ:300233)2025-05-15 10:00Group 1: Company Operations and Product Development - The production of astaxanthin is currently undergoing safety certification review, with plans for market launch initially set for 2024 but now delayed to 2025 [2] - The company is actively communicating to expedite the approval process for astaxanthin [2] - Glutathione is being positioned as a raw material for downstream pharmaceutical production, with licenses obtained for its use in functional foods and health products [3] Group 2: Market Conditions and Financial Performance - The company is managing stable raw material costs and enhancing cost control measures to mitigate the impact of fluctuating crude oil prices on profits [2] - The first quarter profit saw a year-on-year decline, attributed to price reductions in some products due to procurement policies and intensified industry competition [5] - The overall business impact from US-China trade tensions is currently assessed as minimal, with ongoing monitoring of tariff policy changes [5] Group 3: Product Pricing and Market Demand - The price of glutathione has not seen significant changes recently, despite market fluctuations and varying customer requirements [5] - The company is exploring the potential for glutathione to be classified as a new resource food, which could significantly increase demand [2] - The company is tracking developments in the new tobacco sector, focusing on nicotine therapy and harm reduction [5]